Contraindications: This peptide has 5 known contraindication(s). See Safety section

Hormonal & Sexual HealthModerate

Gonadorelin

Also known as: GnRH, LHRH, Gonadotropin-Releasing Hormone, Luteinizing Hormone-Releasing Hormone, Factrel, Lutrepulse

Controlled Substance

FDA Approved

MW: 1182.29 g/mol • 44 amino acids

A synthetic form of gonadotropin-releasing hormone (GnRH) used to stimulate the release of FSH and LH from the pituitary, supporting natural testosterone production and fertility in both men and women.

Half-Life

2-4 minutes

Typical Dose

50-200 mcg

Frequency

1-3x daily or pulsatile

Routes

Subcutaneous

Half-Life Visualization

Half-Life Decay Curve

Concentration over time assuming initial dose = 100%

Gonadorelin(t1/2: 0.05h +/- 0.020000000000000004h)

Use arrow keys to navigate: Left/Right for time, Up/Down for peptides

Shaded areas represent reported half-life variability from published studies.

Peptide	Half-Life	50% at	25% at	12.5% at	Redose Window
Gonadorelin	0.05h	0.05h	0.1h	0.15000000000000002h	0.05h - 0.1h

Showing Gonadorelin decay curve

Open Full Comparison Tool

Mechanism of Action

Gonadorelin is a synthetic decapeptide identical to endogenous gonadotropin-releasing hormone (GnRH), also known as luteinizing hormone-releasing hormone (LHRH). It is the master regulator of the hypothalamic-pituitary-gonadal (HPG) axis.

Primary Mechanism

Pituitary Stimulation

When administered in pulsatile fashion:

Binds to GnRH receptors on pituitary gonadotroph cells
Triggers release of Luteinizing Hormone (LH)
Triggers release of Follicle-Stimulating Hormone (FSH)
Maintains natural feedback mechanisms

Downstream Effects

In males:

LH stimulates Leydig cells to produce testosterone
FSH supports spermatogenesis via Sertoli cells
Preserves testicular function and fertility

In females:

LH triggers ovulation and corpus luteum formation
FSH stimulates follicular development
Supports natural menstrual cycle regulation

Pulsatile vs Continuous Administration

Critical distinction:

Pulsatile: Mimics natural hypothalamic secretion; stimulates gonadotropin release
Continuous: Causes receptor downregulation and desensitization; eventually suppresses axis

This is why timing and dosing pattern are essential for desired outcomes.

Comparison to GnRH Agonists

Feature	Gonadorelin	Long-Acting GnRH Agonists
Half-life	Minutes	Days to months (depot)
Initial effect	Stimulation	Flare then suppression
Long-term effect	Maintains axis	Suppresses axis
Use in TRT	Preserve fertility	Prostate cancer

Research & Evidence

Evidence Level: Gonadorelin has extensive clinical research and FDA approval for diagnostic and therapeutic use. It is one of the most well-studied reproductive peptides.

Fertility Treatment

Hypogonadotropic Hypogonadism

Pulsatile gonadorelin therapy:

Restores normal pulsatile LH/FSH secretion
Induces spermatogenesis in men
Induces ovulation in women
More physiological than gonadotropin injections

Male Fertility Preservation

During testosterone replacement:

Maintains intratesticular testosterone
Preserves spermatogenesis
Alternative to HCG for testicular support
May maintain testicular volume

Testosterone Restoration

Post-Cycle Recovery

After anabolic steroid use:

Helps restart natural testosterone production
Part of comprehensive PCT protocols
Used alongside SERMs and HCG
Supports HPT axis recovery

Age-Related Decline

Research explores:

Stimulating endogenous testosterone
Alternative to TRT in mild hypogonadism
Preserving natural axis function

Diagnostic Use

FDA-approved indications:

Evaluating pituitary function
Distinguishing hypothalamic vs pituitary hypogonadism
Assessing gonadotropin reserve
Timing of puberty onset

Female Applications

Fertility medicine uses:

Ovulation induction in hypothalamic amenorrhea
Support for IVF protocols
Treatment of PCOS-related infertility
More physiological than gonadotropin injections

Dosing

Disclaimer: Gonadorelin is a prescription medication. Use should be supervised by a qualified healthcare provider. Dosing information is for educational reference.

Research Protocols

Administration Methods

Subcutaneous (Most Common)

Standard route for clinical use
Rapid absorption
Can be self-administered
Preferred for regular dosing

Pulsatile Pump Delivery

Mimics natural hypothalamic secretion
Delivers pulses every 60-120 minutes
Most physiological approach
Used in fertility clinics

Timing Considerations

Space doses throughout the day
Avoid continuous infusion (causes suppression)
Morning and evening dosing commonly used
Can be combined with other fertility agents

Reconstitution

When using lyophilized powder:

Reconstitute with bacteriostatic water or saline
Typical concentration varies by protocol
Refrigerate after reconstitution
Use within 7-14 days

Pharmacokinetics

Absorption

IV: Immediate, 100% bioavailable
SC/IM: Rapid, peak within minutes
Very short duration of action
Requires frequent dosing for therapeutic effect

Distribution

Rapid distribution to target tissues
Reaches pituitary quickly
Short circulation time
Minimal tissue accumulation

Metabolism

Rapidly degraded by peptidases
Half-life of only 2-4 minutes
Metabolized in blood, liver, and kidneys
No active metabolites

Elimination

Half-life: 2-4 minutes (very short)
Rapid clearance requires pulsatile delivery
Eliminated primarily via enzymatic degradation
No accumulation with pulsatile dosing

Synergy & Stacking

Gonadorelin + HCG

Dual stimulation approach:

Gonadorelin: Pituitary LH stimulation
HCG: Direct testicular LH-receptor activation
Provides redundant signaling pathways
May be used alternating or in sequence

Gonadorelin + Kisspeptin-10

Upstream and direct stimulation:

Kisspeptin stimulates endogenous GnRH release
Gonadorelin provides direct GnRH receptor activation
Amplified pituitary response
Research protocol combination

Gonadorelin + SERM (Clomiphene/Enclomiphene)

Fertility optimization:

SERM blocks estrogen negative feedback
Gonadorelin provides pulsatile stimulation
Synergistic increase in LH/FSH
Common in male fertility protocols

PCT Stack

Post-cycle recovery:

Gonadorelin for axis stimulation
HCG for testicular support
SERM for estrogen modulation
Comprehensive recovery approach

Safety & Side Effects

Known Side Effects

Common

Headache
Flushing
Nausea
Injection site reactions

Uncommon

Dizziness
Abdominal discomfort
Light-headedness

In Fertility Treatment

Ovarian hyperstimulation syndrome (women)
Multiple pregnancy risk
Mood changes

Serious Risks

Tumor Considerations

Initial hormone surge may stimulate hormone-sensitive tumors
Pituitary apoplexy risk with pituitary adenomas
Requires proper medical evaluation before use

Warning: Gonadorelin should not be used in pregnancy. It can cause fetal harm. Reliable contraception required during treatment cycles.

Long-term Considerations

No significant long-term adverse effects documented with proper use
Pulsatile administration maintains axis function
Continuous administration causes desensitization
Regular monitoring recommended

Monitoring

Baseline Testing

Before starting treatment:

Testosterone levels (total and free)
LH and FSH levels
Estradiol
Semen analysis (fertility cases)
Pituitary function evaluation
Rule out contraindications

During Treatment

Regular monitoring of:

Hormone levels (LH, FSH, testosterone)
Response to stimulation
Side effects
Testicular examination (males)
Ovarian response (females)

Follow-up

Periodic hormone panels
Fertility parameters as appropriate
Adjust dosing based on response
Evaluate need for continued treatment

Regulatory Status

Current Status

Region	Status
United States	FDA-approved (Rx only)
Canada	Prescription medication
European Union	Approved prescription
United Kingdom	Prescription only
Australia	Schedule 4 (Rx)
WADA	Prohibited in sport

Approved Uses

FDA-approved indications:

Diagnostic testing of pituitary function
Treatment of hypogonadotropic hypogonadism
Infertility treatment
Research applications

Legal Considerations

Prescription required in most jurisdictions
Prohibited in competitive sports (WADA banned)
Used off-label in TRT and PCT settings
Legitimate medical uses are well-established

References

[] Conn PM, Crowley WF Jr.. Gonadotropin-releasing hormone and its analogs. Annual Review of Medicine () doi:10.1146/annurev.med.45.1.391

[] Santen RJ, Bardin CW.. Episodic luteinizing hormone secretion in man. Journal of Clinical Investigation () doi:10.1172/JCI107327

[] Schally AV.. LH-RH analogues: I. Their impact on reproductive medicine. Gynecological Endocrinology () doi:10.3109/09513599909167350

[] Hayes FJ, et al.. Use of a gonadotropin-releasing hormone antagonist as a physiologic probe in polycystic ovary syndrome. Journal of Clinical Endocrinology & Metabolism () doi:10.1210/jcem.83.7.4920

[] Reproductive Endocrinology Review. GnRH Pulsatile Therapy: Applications in Male and Female Infertility. Fertility and Sterility ()

Community Insights

Limited Data

Aggregated from 14 self-reported experiences collected from public forums.

Overall Sentiment

Neutral(-0.06)

21.4% positive42.9% neutral35.7% negative

Reported Benefits

felt the best i've ever felt in my adult life1x
healthy markers1x
helped achieve weight loss goals1x

Reported Side Effects

mental state crashes1x
energy depletion1x
tiredness1x
anxiety1x
depression1x
difficulty focusing1x

Common Doses Reported

0.1mg 2x/week1 report
1mg1 report
50mg twice per week1 report
500mcg1 report
2 times a week1 report

Administration Routes

oral1 report
sublingual1 report
subcutaneous1 report
intramuscular1 report

This data reflects self-reported user experiences collected from public forums. It is not medical advice. Individual results vary. Always consult a qualified healthcare professional before using any research compound.

Get Our Free Peptide Research Guide

100 essential tips for safe peptide research, delivered as a free PDF.

Need Research Supplies?

Syringes, bacteriostatic water, vials, alcohol swabs, and more. Everything you need for peptide research.

Browse Supplies

Related Tips for Gonadorelin

Tip #92science